Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 1, 1996, Pages 21-30

  Koyama, Eriko ^a   Chiba, Kan ^a   Tani, Masanao ^a   Ishizaki, Takashi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; DESIPRAMINE; FURAFYLLINE; MEPHENYTOIN; MIANSERIN; PHENACETIN; QUINIDINE; TESTOSTERONE; TROLEANDOMYCIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; ENANTIOMER; ENZYME ACTIVITY; ENZYME KINETICS; FEMALE; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; PRIORITY JOURNAL; STEREOCHEMISTRY;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; KINETICS; LIVER; MIANSERIN;

EID: 0030434501     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. BEGC, E. J., SHARMAN, J. R., KIDD, J. E., SAINSBURY, R. AND CLARK, D. W. J.: Variablility in the elimination of mianserin in elderly patients. Br. J. Clin. Pharmacol. 27: 445-451, 1989.
2. BRØSEN, K., SKJELBO, E., RASMUSSEN, B. B., POULSEN, H. E. AND LOFT, S.: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45: 1211-1214, 1993.
3. BRØSEN, K., ZEUGIN, T. AND MEYER, U. A.: Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther. 49: 609-617, 1991.
4. CHIBA, K., KOBAYASHI, K., MANABE, K., TANI, M., KAMATAKI, T. AND ISHIZAKI, T.: Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. J. Pharmacol. Exp. Ther. 266: 52-59, 1993a.
5. CHIBA, K., KOBAYASHI, K., TANI, M., MANABE, K. AND ISHIZAKI, T.: The kinetic characterization of S-mephenytoin 4-hydroxylase (P-450IICMP) activity in human liver samples obtained as surgical waste from Japanese patients. Drug Metab. Dispos. 21: 747-749, 1993b.
6. CHIBA, K., KUBOTA, E., MIYAKAWA, T., KATO, Y. AND ISHIZAKI, T.: Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine in mice. J. Pharmacol. Exp. Ther. 246: 1108-1115, 1988.
7. CHIBA, K., SAITOH, A., KOYAMA, E., TANI M., HAYASHI, M. AND ISHIZAKI, T.: The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: A two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br. J. Clin. Pharmacol. 37: 237-242, 1994.
8. CREWE, H. K., LENNARD, M. S., TUCKER, G. T., WOODS, F. R. AND HADDOCK, R. E.: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br, J. Clin. Pharmacol. 34: 262-265, 1992.
9. DAHL, M.-L. AND BERTILSSON, L.: Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3: 61-70, 1993.
10. DAHL, M.-L., TYBRING, G., ELWIN, C.-E., ALM, C., ANDREASSON, K., GYLLENPALM, M. AND BERTILSSON, L.: Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. Clin. Pharmacol. Ther. 56: 176-183, 1994.
11. DAHL-PUUSTINEN, M. L., LIDEN, A., ALM, C., NORDIN, C. AND BERTILSSON, L.: Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin. Pharmacol. Ther. 46: 78-81, 1989.
12. DAWLING, S., FORD, S., ARIYANAYAGAM, P., O'NEAL, H. AND LEWIS, R. R.: Plasma concentrations of mianserin after single dose and at steady-state in depressed elderly patients. Clin. Pharmacokinet. 12: 73-78, 1987.
13. DELBRESSINE, L. P. C., MOONEN, M. E. G., KASPERSEN, F. M., JACOBS, P. L. AND WAGENAARS, G. L.: Biotransformation of mianserin in laboratory animals and man. Xenobiotica 22: 227-236, 1992.
14. FISCHER, V., VOGELS, B., MAURER, G. AND TYNES, R. E.: The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombitiant cytochrome P4502D6. J. Pharmacol. Exp. Ther. 260: 1355-1360, 1992.
15. GOLDSTEIN, J. A. AND DE MORAIS, S. M. F.: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.
16. KOBAYASHI, S., MURRAY, S., WATSON, D., SESARDIC, D., DAVIES, D. S. AND BOOBIS, A. R.: The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine is the inverse of that in man. Biochem. Pharmacol. 38: 2795-2799, 1989.
17. KOYAMA, E., SOHN, D.-R., SHIN, S.-G., CHIBA, K., SHIN, J.-G., KIM, Y.-H., ECHIZEN, H. AND ISHIZAKI, T.: Metabolic disposition of imipramine in Oriental subjects: Relation to metoprolol α-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. J. Pharmacol. Exp. Ther. 271: 860-867, 1994.
18. KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. AND MEYER, U. A.: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36: 89-96, 1989.
19. KUNZE, K. L. AND TRAGER, W. F.: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6: 649-656, 1993.
20. LAMBERT, C., PARK, B. K. AND KITTERINGHAM, N. R.: Activation of mianserin and its metabolites by human liver microsomes. Biochem. Pharmacol. 38: 2853-2858, 1989.
21. LEMOINE, A., GAUTIER, J. C., AZOULAY, D., KIFEK, L., BELLOC, C., GUENGERICH, F. P., MAUREL, P., BEAUNE, P. AND LEROUX, J. P.: Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 43: 827-832., 1993.
22. LLERENA, A., ALM, C., DAHL, M.-L., EKQVIST, B. AND BERTILSSON, L.: Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit. 14: 92-97, 1992.
23. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
24. MONTOGOMERY, S., MCAULEY, R. AND MONTOGOMERY, D. B.: Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens. Br. J. Clin. Pharmacol. 5: 71S-76S, 1978.
25. NAWISHY, S., HATHWAY, N. AND TURNER, P.: Interactions of anticonvulsant drugs with mianserin and nomifensin. Lancet 2: 871-872, 1981.
26. OTANI, K., KANEKO, S., SASA, H., KONDO, T. AND FUKUSHIMA, Y.: Is there a therapeutic window for plasma concentration of mianserin plus desmethylmianserin? Human Psychopharmacol. 3: 243-248, 1991.
27. OTTON, S. V., Wu, D., JOFFE, R. T., CHEUNG, S. W. AND SELLERS, E. M.: Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin. Pharmacol. Ther. 53: 401-409, 1993.
28. PINDER, R. M. AND VAN DELFT, A, M. L.: The potential therapeutic role of the enantiomers and metabolites of mianserin. Br. J. Clin. Pharmacol. 15: 269S-276S, 1983.
29. RASMUSSEN, B. B., MAENPAA, J., PELKONEN, O., LOFT, S., POULSEN, H. E., LYKKESFELDT, J. AND ERBSEN, K.: Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. Br. J. Clin. Pharmacol. 39: 151-159, 1995.
30. SHIMADA, T., YAMAZAKI. H., MIURA, M., INUI, Y. AND GUENGERICH, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
31. SINDRUP, S. H., BRØSEN, K., GRAM, L. F., HALLAS, J., SKJELBO, E., ALLEN, A., ALLEN, G. D., COOPER, S. M., MELLOWS, G., TASKER, T. C. G. AND ZUSSMANN, B. D.: The relationship between paroxetine and the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 51: 278-287, 1992.
32. SKJELBO, E. AND BRØSEN, K.: Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34: 256-261, 1992.
33. STEVENS, J. C. AND WRIGHTON, S. A.: Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver microsomes P450. J. Pharmacol. Exp. Ther. 266: 964-971, 1993.
34. TACKE, U., LEINONEN, E., LILLSUNDE, P., SEPPALA, T., ARVELA, P., PELKONEN, O. AND YLITALO, P.: Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations. J. Clin. Psychopharmacol. 12: 262-267, 1992.
35. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. AND MINERS, J. O.: Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265: 401-407, 1993.
36. THUMMEL, K. E., KHARASH, E. D., PODOLL, T. AND KUNZE, K.: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos. 21: 350-357, 1993.
37. VON BAHR, C., MOVIN, G., NORDIN, C., LIDEN, A., MAMMERLUND-UDENAES, M., HEDBERG, A., RING, H. AND SJÖQVIST, F.: Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther. 49: 234-240, 1991.
38. VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU, M. M., HARMATZ, J. S. AND SHADER, R. I.: Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br. J. Clin. Pharmacol. 38: 23-31, 1994.
39. WATKINS, P. B., WRIGHTON, S. A., MAUREL, P., SCHUETZ, E. G., MENDEZ-PICON, G., PARKER, G. A. AND GUZELIAN, P. S.: Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. U.S.A. 82: 6310-6314, 1985.
40. 3 receptors. J. Pharm. Pharmacol. 45: 711-714, 1993.
41. WRIGHTON, S. A. AND STEVENS, J. C.: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22: 1-21, 1992.
42. YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, T. AND UNO, T.: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiol. Dyn. 4: 879-885, 1981.
43. YASUMORI, T., MURAYAMA, N., YAMAZOE, Y. AND KATO, R.: Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clin. Pharmacol. Ther. 47: 313-322, 1990.
44. YOSHIMOTO, K., ECHIZEN, H., CHIBA, K., TANI, M. AND ISKIZAKI, T.: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers - N-desisopropylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol. 39: 421-431, 1995.
45. ZIEGLER, D. M.: Bioactivation of xenobiotics by flavin-containing monooxygenases. In Biological Reactive Intermediates. IV. Molecular and Cellular Effects and Their Impact on Human Health, ed. by C. M. Witmer, R. R. Snyder, D. J. Jollow, G. F. Kalf, J. J. Kocsis and I. G. Sipes, pp. 41-50, Plenum Press, New York, 1990.